Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Purpose: Concomitant temozolomide (TMZ)/radiotherapy followed by adjuvant TMZ has increased survival in patients with glioblastoma multiforme (GBM). However, few options are effective for patients who experience treatment failure. We conducted a multicenter, phase II study to assess the efficacy and safety of continuous dose-intense TMZ for recurrent GBM. Patients and Methods: Patients with malignant glioma at progression after standard TMZ 150 to 200 mg/m 2 × 5 days in a 28-day cycle for three or more cycles were stratified by tumor type (anaplastic glioma group A, GBM, group B). Ninety-one patients with GBM were prospectively divided into three groups (early [B1], extended [B2], and rechallenge [B3]) according to the timing of progression during adjuvant therapy. All patients received continuous dose-intense TMZ 50 mg/m 2 /d for up to 1 year or until progression occurred. Response was assessed by using RECIST (Response Evaluation Criteria in Solid Tumors). Results: A total of 116 of 120 patients were evaluable for efficacy. For patients with GBM, 6-month progression-free survival (PFS) was 23.9% (B1, 27.3%; B2, 7.4%; B3, 35.7%). One-year survival from time of study entry was 27.3%, 14.8%, and 28.6% for the B1, B2 and B3 groups, respectively. For patients with anaplastic glioma, 6-month PFS was 35.7%; 1-year survival was 60.7%. The most common grades 3 and 4 nonhematologic toxicities were nausea/vomiting (6.7%) and fatigue (5.8%). Grades 3 and 4 hematologic toxicities were uncommon. Conclusion: Rechallenge with continuous dose-intense TMZ 50 mg/m 2 /d is a valuable therapeutic option for patients with recurrent GBM. Patients who experience progression during the first six cycles of conventional adjuvant TMZ therapy or after a treatment-free interval get the most benefit from therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationNew Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Self-citationMGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationHammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
The anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902
Cited by
Glioblastoma and Other Malignant Gliomas: A Clinical Review
Omuro, A. (2013) · JAMA · doi:10.1001/jama.2013.280319 · Cited by 2,301
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Primary brain tumours in adults
Lapointe, S., Perry, A., & Butowski, N. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30990-5 · Cited by 1,366
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Weller, M., van den Bent, M., Tonn, J. C., Stupp, R., Preusser, M., Cohen-Jonathan-Moyal, E., Henriksson, R., Rhun, E. L., Balana, C., Chinot, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,088
Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862
Standards of care for treatment of recurrent glioblastoma—are we there yet?
Weller, M., Cloughesy, T., Perry, J. R., & Wick, W. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos273 · Cited by 771
Self-citationEANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
Weller, M., van den Bent, M., Hopkins, K., Tonn, J. C., Stupp, R., Falini, A., Cohen-Jonathan-Moyal, E., Frappaz, D., Henriksson, R., Balana, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70011-7 · Cited by 750
Advances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662
MGMT testing—the challenges for biomarker-based glioma treatment
Wick, W., Weller, M., van den Bent, M., Sanson, M., Weiler, M., von Deimling, A., Plass, C., Hegi, M., Platten, M., & Reifenberger, G. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.100 · Cited by 579
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Nabors, L. B., Portnow, J., Ahluwalia, M., Baehring, J., Brem, H., Brem, S., Butowski, N., Campian, J. L., Clark, S. W., Fabiano, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0052 · Cited by 539
Self-citationRecurrent glioma clinical trial, CheckMate-143: the game is not over yet
Filley, A. C., Henriquez, M., & Dey, M. (2017) · Oncotarget · doi:10.18632/oncotarget.21586 · Cited by 386
Wen, P. Y., Stein, A., van den Bent, M., De Greve, J., Wick, A., de Vos, F. Y. F. L., von Bubnoff, N., van Linde, M. E., Lai, A., Prager, G. W., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00578-7 · Cited by 369
Self-citationWeller, M., Tabatabai, G., Kästner, B., Felsberg, J., Steinbach, J. P., Wick, A., Schnell, O., Hau, P., Herrlinger, U., Sabel, M. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2737 · Cited by 319
Temozolomide for immunomodulation in the treatment of glioblastoma
Karachi, A., Dastmalchi, F., Mitchell, D. A., & Rahman, M. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy072 · Cited by 300
Nonsurgical Treatment of Recurrent Glioblastoma
Gallego, O. (2015) · Current Oncology · doi:10.3747/co.22.2436 · Cited by 296
Drug rechallenge and treatment beyond progression—implications for drug resistance
Kuczynski, E. A., Sargent, D. J., Grothey, A., & Kerbel, R. S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.158 · Cited by 286
Ringel, F., Pape, H., Sabel, M., Krex, D., Bock, H. C., Misch, M., Weyerbrock, A., Westermaier, T., Senft, C., Schucht, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov145 · Cited by 267
Drug Resistance in Glioblastoma: A Mini Review
Haar, C. P., Hebbar, P., Wallace, G. C., Das, A., Vandergrift, W. A., Smith, J. A., Giglio, P., Patel, S. J., Ray, S. K., & Banik, N. L. (2012) · Neurochemical Research · doi:10.1007/s11064-011-0701-1 · Cited by 254
Shi, W., Blumenthal, D. T., Oberheim Bush, N. A., Kebir, S., Lukas, R. V., Muragaki, Y., Zhu, J.-J., & Glas, M. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03540-6 · Cited by 61
Treatment considerations for MGMT-unmethylated glioblastoma
Taylor, J. W., & Schiff, D. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0507-z · Cited by 60
Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches
Gilbert, M. R. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.09.008 · Cited by 45
Bakas, S., Vollmuth, P., Galldiks, N., Booth, T. C., Aerts, H. J. W. L., Bi, W. L., Wiestler, B., Tiwari, P., Pati, S., Baid, U., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00315-2 · Cited by 36
Self-citation
Metadata
- Authors
- Perry, J. R., Bélanger, K., Mason, W. P., Fulton, D., Kavan, P., Easaw, J., Shields, C., Kirby, S., Macdonald, D. R., Eisenstat, D. D., Thiessen, B., Forsyth, P., & Pouliot, J.-F.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-04-20
- Volume
- 28
- Issue
- 12
- Pages
- 2051-2057
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2148923175
- Cited by
- 384
- References
- 40
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.